GlycoMimetics, Inc., a biopharmaceutical company, engages in the design and development of small molecule therapeutics to mimic the functions of bioactive carbohydrates. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa. The company was founded in 2003 and is based in Gaithersburg, Maryland.
Current Team (9)Update
Chairman of the Board of Directors
Chief Financial Officer
Chief Executive Officer & Board of Directors
Vice President and Chief Scientific Officer, Board of Directors
Funding Rounds (2) - $77MUpdate
Global venture capital firm helping entrepreneurs build transformational businesses across...
Anthem Capital Management is an early stage venture firm that invests in companies in the...
Sanofi-Genzyme BioVentures (SGBV) is an important component of Sanofi’s broader global strategy...
101 Orchard Ridge Drive
Gaithersburg, MD 20878